RVNC earnings call for the period ending March 31, 2019.
News & Analysis: Revance Therapeutics
RVNC earnings call for the period ending December 31, 2018.
Find out which of these stocks got a buyout bid.
Upbeat news from two phase 3 trials is met with investor enthusiasm.
Investors were cautious towards the end of the trading week as the UK's vote to leave the EU looms.
The company's most advanced treatment has failed in late-stage clinical studies.
Interim results from a mid stage trial could mean that Revance Therapeutics has a better-than-Botox drug in development.
Sarepta Therapeutics, Revance Therapeutics, and Cytokinetics saw big moves recently; MannKind and Orexigen could be next.
Merger and acquisition deals and rumors were the talk of the town this week, while three additional clinical and filing updates led to double-digit percentage moves.
M&A activity sends the S&P 500 decisively higher as GW Pharmaceuticals, Revance Therapeutics, and Allergan all jump by double digits.